Technimark Earns MedAccred Certification for El Paso Facility

Technimark announced today that its production facility in El Paso, Texas, received its MedAccred certification from the Performance Review Institute. The facility, which is also ISO 13485:2016 certified and 21 CFR 820 compliant, specializes in medical contract manufacturing, including services such as custom injection molding, assembly and logistics operations for the medical device industry.

“Patient safety and quality are our highest priorities, and we are excited to partner with MedAccred to ensure our critical processes are best-in-class,” said Kris Peavy, president of Technimark’s Healthcare division. “The significant growth of our medical device business around the world, and specifically in our El Paso facility, made MedAccred certification a perfect fit. We’re currently pursuing accreditation at all of our medical device facilities, and we expect them to be certified in the near future.

”According to Mr. Peavy, Technimark sees the MedAccred program as beneficial for patients, customers and the company. “The accreditation helps us further demonstrate our expertise as a trustworthy and high-quality supplier in the medical device industry. The assessment uses criteria established directly by customers and experts across the industry, and it is a great way to demonstrate our commitment to our customers’ needs.”

The MedAccred certification program was developed by the Performance Review Institute, a non-for-profit organization that facilitates collaborative supply chain oversight programs, quality management systems approvals and professional development activities in industries that rely on high-quality, high-safety protocols. MedAccred is managed by the medical device OEMs, contract manufacturers and suppliers who collaborate to provide the sector with a trustworthy, evidence-based tool to ensure the suppliers’ processes and products meet the highest standards and improve product quality.

“Technimark is clearly committed to quality and improving patient safety by meeting the rigorous requirements set by technical experts in the medical device industry,” said Connie Conboy, director, MedAccred. “Technimark is a true leader in the medical device industry as demonstrated by their MedAccred Accreditation for Plastics Injection Molding at their El Paso, Texas facility.”

 

In describing the MedAccred certification process, the Performance Review Institute notes that preventing output deficiencies requires that critical processes and products be validated during manufacturing to prove that they are fit for purpose, satisfy regulatory requirements and reduce overall risk. The MedAccred certification does just this by:

  • Providing consistent, standardized critical process accreditation accepted by the Medical Device Industry resulting in fewer redundant onsite audits by multiple OEMs
  • Having Subject Matter Experts conduct in-depth critical process audits that are compliant and consistent with accepted industry/technical standards
  • Providing greater visibility of the supply chain to all levels and sub-tiers that provide critical processes, consistent with regulatory requirements (e.g., FDA, ISO 13485, MDD/MDR, etc.)
  • Improving the flow down of OEM requirements to sub-tier suppliers
  • Applying medical device industry-accepted and consistent technical requirements that yield process discipline, greater operational efficiency and continuous improvement resulting in higher quality and lower overall cost

Mr. Peavy explained that the audit is very thorough and drills into each individual process under review. “While MedAccred certification requires an ISO-certified quality management system, the process is not simply a QMS audit. Rather, it focuses on the key elements of the manufacturing process itself,” he said.

Audits are conducted by industry-approved and trained SME auditors on behalf of its subscribing OEM members using collaboratively created audit criteria. The accreditation is granted and accepted by the program’s subscribing OEM members. The audit criteria incorporate industry-accepted performance standards and manufacturer specifications that meet regulatory requirements.

“On behalf of Technimark and our clients, I want to thank the entire El Paso team for leading the way on this notable achievement,” Mr. Peavy said.

 

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”